FAM133B

Across TCGA pan-cancer cohorts, FAM133B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM133B data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FAM133B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM133B expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

UCEC, LSCC, and PDAC are the cancer types where FAM133B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.570	1.000	.038	8	view →
LSCC	DFS	Quartile	All	0.844	0.178	.010	5	view →
PDAC	DFS	Median	III,IV	0.472	0.228	.031	4	view →
HNSC	DFS	Tertile	All	0.569	0.823	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM133B–UCEC (DFS)

Open the UCEC breakdown →